Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the ...

Respondents agreed that the level of risk in pharmaceutical supply chains has increased across the board since 2023, although perceptions about the degree of escalation vary. Fifty-six (56%) percent ...